Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Classification of outcomes in antimalarial therapeutic efficacy studies with Aster.

Antimicrobial agents and chemotherapy - 6 May 2026

Gerlovina Inna, Berube Sophie, Briggs Jessica, Murie Kathryn, Murphy Maxwell, Wesolowski Amy, Greenhouse Bryan

Abstract excerpt

Reliable assessment of antimalarial drug efficacy is crucial for an effective response to emerging drug resistance, and therapeutic efficacy studies (TESs) are the primary means of estimating in vivo efficacy. The accuracy of such estimates rests on correctly classifying recurrent infections developed during follow-up as recrudescences or new infections. Genotyping is used to guide classification, but polyclonal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Algorithms
Share to Alleles
Share to Antimalarials

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance

Share to Gene Frequency

Share to Malaria, Falciparum

Share to Plasmodium falciparum

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 41973078
DOI: 10.1128/aac.01411-25
PMCID: PMC13148033

Genes

TES

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Classification of outcomes in antimalarial therapeutic efficacy studies with Aster.PMID 41973078Read ↗

Impact of transmission intensity on the accuracy of genotyping to distinguish recrudescence from new infection in antimalarial clinical trials.Semantic proximity Read ↗

Molecular genotyping to distinguish between recrudescents and new infections in treatment trials of Plasmodium falciparum malaria conducted in Sub-Saharan Africa: adjustment of parasitological outcomes and assessment of genotyping effectiveness.Semantic proximity Read ↗

Microhaplotype deep sequencing assays to capture Plasmodium vivax infection lineagesSemantic proximity Read ↗

Revisiting <i>Plasmodium vivax</i> molecular correctionSemantic proximity Read ↗

Should deep-sequenced amplicons become the new gold-standard for analysing malaria drug clinical trials?Semantic proximity Read ↗

Robust Algorithm for Systematic Classification of Malaria Late Treatment Failures as Recrudescence or Reinfection Using Microsatellite Genotyping.Semantic proximity Read ↗

MOIRE: a software package for the estimation of allele frequencies and effective multiplicity of infection from polyallelic data.Semantic proximity Read ↗

Distinguishing recrudescences from new infections in antimalarial clinical trials: major impact of interpretation of genotyping results on estimates of drug efficacy.Semantic proximity Read ↗

The use of genotyping in antimalarial clinical trials: a systematic review of published studies from 1995-2005.Semantic proximity Read ↗

In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia.Semantic proximity Read ↗

Comparison of Two Genotyping Methods for Distinguishing Recrudescence from Reinfection in Antimalarial Drug Efficacy/Effectiveness Trials.Semantic proximity Read ↗

Distinguishing new from persistent infections at the strain level using longitudinal genotyping dataSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.